Difference between revisions of "Penile cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.'''" to "<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.'''-->")
m (Text replacement - "'''contains dosing details in abstract'''" to "'''dosing details in abstract have been reviewed by our editors'''")
 
(114 intermediate revisions by 4 users not shown)
Line 1: Line 1:
<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
+
<span id="BackToTop"></span>
 
+
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
<!--
+
[[#top|Back to Top]]
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].
+
</div>
-->
+
{{#lst:Editorial board transclusions|gu}}
{| class="wikitable" style="text-align:center; width:50%;"
 
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
 
|-
 
|style="background-color:#F0F0F0"|[[File:aymen_elfiky.jpg|frameless|upright=0.3|center]]
 
|<big>[[User:Aymenelfiky|Aymen Elfiky, MD, MSc, MBA]]<br>Boston, MA</big><br>[https://www.linkedin.com/in/aymen-elfiky-15420873/ LinkedIn]
 
|-
 
|}
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div>
+
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div>
+
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 +
=Guidelines=
 +
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 +
==EAU/ASCO==
 +
*'''2023:''' Brouwer et al. [https://doi.org/10.1016/j.eururo.2023.02.027 European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update] [https://pubmed.ncbi.nlm.nih.gov/36906413 PubMed]
  
=Guidelines=
+
==[https://www.esmo.org/ ESMO]==
==[http://www.esmo.org/ ESMO]==
+
*'''2013:''' Van Poppel et al. [https://www.esmo.org/Guidelines/Genitourinary-Cancers/Penile-Carcinoma Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/23975666 PubMed]
*[http://annonc.oxfordjournals.org/content/24/suppl_6/vi115.full.pdf+html Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/23975666 PubMed]
 
  
==[https://www.nccn.org/ NCCN]==
+
==NCCN==
*[https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf NCCN Guidelines - Penile Cancer]
+
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1456 NCCN Guidelines - Penile Cancer]
 +
**'''2013:''' Clark et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4042432/ Penile cancer: Clinical Practice Guidelines in Oncology] [https://pubmed.ncbi.nlm.nih.gov/23667209/ PubMed]
  
 
=Neoadjuvant chemotherapy=
 
=Neoadjuvant chemotherapy=
 
 
==TIP {{#subobject:fe995|Regimen=1}}==
 
==TIP {{#subobject:fe995|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|[[#top|back to top]]
 
|}
 
 
TIP: '''<u>T</u>'''axol (Paclitaxel), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
 
TIP: '''<u>T</u>'''axol (Paclitaxel), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:b81dfa|Variant=1}}===
 
===Regimen {{#subobject:b81dfa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!Study
+
!style="width: 33%"|Study
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940402/ Pagliaro et al. 2010]
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940402/ Pagliaro et al. 2010 (MDACC ID99-194)]
|style="background-color:#91cf61"|Phase II
+
|2000-04 to 2008-09
 +
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
 
|}
 
|}
 +
''Note: cycle was repeated on day 22 if the patient's ANC was at least 1400/μL and platelet count was at least 100 x 10<sup>9</sup>/L. Some guidelines state that it is reasonable to give adjuvant TIP if it was not given preoperatively and pathology shows high-risk features, or to give first-line TIP in the metastatic setting; to our knowledge, there are no primary references to support this practice.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
 
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
Line 48: Line 44:
 
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 3
 
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 3
 
**Administered intravenously in 250 mL of normal saline containing 12.5 g of mannitol
 
**Administered intravenously in 250 mL of normal saline containing 12.5 g of mannitol
 
+
====Supportive therapy====
====Supportive medications====
+
*[[Mesna (Mesnex)]] 400 mg/m<sup>2</sup> IV once per day on days 1 to 3, prior to each dose of ifosfamide, then 200 mg/m<sup>2</sup> IV twice per day on days 1 to 3, at 4 and 8 hours after each dose of ifosfamide
*[[Mesna (Mesnex)]] as follows:
+
*[[:Category:Hydration|hydration]] with 3 liters of a solution of 5% dextrose, sodium chloride, potassium chloride, magnesium sulfate, and mannitol, given after cisplatin
**400 mg/m<sup>2</sup> IV once before each dose of [[Ifosfamide (Ifex)]]
 
**200 mg/m<sup>2</sup> IV given twice, at 4 and 8 hours after each dose of [[Ifosfamide (Ifex)]]
 
*After [[Cisplatin (Platinol)]], hydration with 3 liters of a solution of 5% dextrose, sodium chloride, potassium chloride, magnesium sulfate, and mannitol
 
 
*One of the following dexamethasone doses:
 
*One of the following dexamethasone doses:
**[[Dexamethasone (Decadron)]] 8 mg IV once 1 hour before [[Paclitaxel (Taxol)]]
+
**[[Dexamethasone (Decadron)]] 8 mg IV once 1 hour prior to paclitaxel
**[[Dexamethasone (Decadron)]] 20 mg PO given twice, at 12 and 6 hours before [[Paclitaxel (Taxol)]]
+
**[[Dexamethasone (Decadron)]] 20 mg PO given twice, at 12 and 6 hours prior to paclitaxel
*[[Diphenhydramine (Benadryl)]] 50 mg IV once prior to [[Paclitaxel (Taxol)]]
+
*[[Diphenhydramine (Benadryl)]] 50 mg IV once on day 1, prior to paclitaxel
 
*One of the following H2 blockers:
 
*One of the following H2 blockers:
**[[Cimetidine (Tagamet)]] 300 mg IV once prior to [[Paclitaxel (Taxol)]]
+
**[[Cimetidine (Tagamet)]] 300 mg IV once on day 1, prior to paclitaxel
**[[Ranitidine (Zantac)]] 50 mg IV once prior to [[Paclitaxel (Taxol)]]
+
**[[Ranitidine (Zantac)]] 50 mg IV once on day 1, prior to paclitaxel
**[[Famotidine (Pepcid)]] 20 mg IV once prior to [[Paclitaxel (Taxol)]]
+
**[[Famotidine (Pepcid)]] 20 mg IV once on day 1, prior to paclitaxel
 
*"The use of prophylactic G-CSF was allowed but not required"
 
*"The use of prophylactic G-CSF was allowed but not required"
 
+
'''21- to 28-day cycle for 4 cycles'''
'''21 to 28-day cycle for 4 cycles; "cycle was repeated on day 22 if the patient's ANC was at least 1400/uL and platelet count was at least 100 x 10<sup>9</sup>/L"'''
+
</div>
 +
<div class="toccolours" style="background-color:#cbd5e7">
 +
====Subsequent treatment====
 +
*[[Surgery#Surgical_resection|Surgery]]
 +
</div></div>
  
 
===References===
 
===References===
# Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. Epub 2010 Jul 12. [http://jco.ascopubs.org/content/28/24/3851.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940402/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20625118 PubMed]
+
# '''MDACC ID99-194:''' Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2010.29.5477 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940402/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20625118/ PubMed] [https://clinicaltrials.gov/study/NCT00512096 NCT00512096]
 
+
==VBM (Vincristine) {{#subobject:fdb0db|Regimen=1}}==
==VBM {{#subobject:fdb0db|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|[[#top|back to top]]
 
|}
 
 
VBM: '''<u>V</u>'''incristine, '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate
 
VBM: '''<u>V</u>'''incristine, '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate
 
+
<div class="toccolours" style="background-color:#ee6b6e">
 
===Regimen {{#subobject:a25051|Variant=1}}===
 
===Regimen {{#subobject:a25051|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!Study
+
!style="width: 33%"|Study
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[http://www.tandfonline.com/doi/full/10.3109/02841868809094366 Pizzocaro et al. 1988]
+
|[https://doi.org/10.3109/02841868809094366 Pizzocaro et al. 1988]
|style="background-color:#ffffbe"|Pilot, <20 pts
+
|1979-1985
 +
|style="background-color:#ffffbe"|Pilot, fewer than 20 pts
 
|-
 
|-
 
|}
 
|}
 
+
''Note: this is of historic interest given the toxicity of bleomycin-containing regimens.''
''Note: ''The NCCN, Penile Cancer version 1.2013, says that "bleomycin-containing regimens were associated with unacceptable toxicity and are no longer recommended. Adjuvant therapy starts 2 to 4 weeks after surgery."''
+
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Surgical_resection|Surgery]], within 2 to 4 weeks
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 15 mg IM twice per week, '''6 hours and 24 hours after vincristine'''
+
*[[Vincristine (Oncovin)]] 1 mg IV once on day 1
*[[Vincristine (Oncovin)]] 1 mg IV once per week
+
*[[Bleomycin (Blenoxane)]] 15 mg IM once per day on days 1 & 2, '''given 6 hours and 24 hours after vincristine'''
*[[Methotrexate (MTX)]] 30 mg PO once per week, '''48 hours after vincristine'''
+
*[[Methotrexate (MTX)]] 30 mg PO once on days 3, '''given 48 hours after vincristine'''
 
+
'''7-day cycle for 12 cycles'''
'''12-week course'''
+
</div>
 
+
<div class="toccolours" style="background-color:#cbd5e7">
 +
====Subsequent treatment====
 +
*[[Surgery#Surgical_resection|Surgery]]
 +
</div></div>
 
===References===
 
===References===
# Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4. [http://www.tandfonline.com/doi/full/10.3109/02841868809094366 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2466471 PubMed]  
+
# Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4. [https://doi.org/10.3109/02841868809094366 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/2466471/ PubMed]  
# '''Review''': Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [http://link.springer.com/article/10.1007%2Fs00345-008-0310-z link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18682961 PubMed]
+
# '''Review:''' Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [https://doi.org/10.1007/s00345-008-0310-z link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18682961/ PubMed]
 
 
 
=Adjuvant chemotherapy=
 
=Adjuvant chemotherapy=
==TIP==
+
==DCF {{#subobject:118691|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
+
DCF: '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
|-
+
<div class="toccolours" style="background-color:#eeeeee">
|[[#top|back to top]]
 
|}
 
''Note: No primary reference available, but the NCCN, Penile Cancer version 1.2013, says that "it is reasonable to give [[#TIP|4 courses of TIP]] in the adjuvant setting if it was not given preoperatively and the pathology shows high-risk features." (see neoadjuvant chemotherapy section)''
 
 
 
==TPF (Taxotere) {{#subobject:118691|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|[[#top|back to top]]
 
|}
 
TPF: '''<u>T</u>'''axotere (Docetaxel), '''<u>P</u>'''latinol (Cisplatin), '''<u>F</u>'''luorouracil
 
 
 
 
===Regimen {{#subobject:a57146|Variant=1}}===
 
===Regimen {{#subobject:a57146|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable" style="width: 40%; text-align:center;"  
!Study
+
!style="width: 25%"|Study
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[http://jco.ascopubs.org/content/29/22/e650.long Necchi et al. 2011]
+
|[https://doi.org/10.1200/jco.2011.34.8367 Necchi et al. 2011]
 
|style="background-color:#ffffbe"|Case report
 
|style="background-color:#ffffbe"|Case report
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[Surgery#Surgical_resection|Surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
 
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
 
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
 
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4
+
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 3000 mg/m<sup>2</sup>)
 
 
 
'''21-day cycle for 3 cycles'''
 
'''21-day cycle for 3 cycles'''
 
+
</div></div>
 
===References===
 
===References===
# Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [http://jco.ascopubs.org/content/29/22/e650.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21632506 PubMed]
+
# '''Case report:''' Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [https://doi.org/10.1200/jco.2011.34.8367 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21632506/ PubMed]
  
 
=Metastatic or unresectable disease=
 
=Metastatic or unresectable disease=
 
 
==BMP {{#subobject:ab9e5f|Regimen=1}}==
 
==BMP {{#subobject:ab9e5f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|[[#top|back to top]]
 
|}
 
 
BMP: '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin)
 
BMP: '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin)
 
<br>MPB: '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin), '''<u>B</u>'''leomycin
 
<br>MPB: '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin), '''<u>B</u>'''leomycin
===Regimen #1 {{#subobject:8938|Variant=1}}===
+
<div class="toccolours" style="background-color:#ee6b6e">
{| class="wikitable" style="width: 100%; text-align:center;"  
+
===Regimen variant #1 {{#subobject:8938|Variant=1}}===
!Study
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Study
 +
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[http://www.jurology.com/article/S0022-5347(05)68815-5/abstract Haas et al. 1999 (SWOG 8520)]
+
|[https://doi.org/10.1016/S0022-5347(05)68815-5 Haas et al. 1999 (SWOG 8520)]
|style="background-color:#91cf61"|Phase II
+
|1986-1994
 +
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
 
|}
 
|}
 
+
''Note: This is likely of historic interest due to the toxicity of bleomycin-containing regimens. Bleomycin was discontinued when a total cumulative dose of 200 units/m<sup>2</sup> was reached.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV bolus once per day on days 1 & 8
+
*[[Bleomycin (Blenoxane)]] as follows:
**Chemotherapy with bleomycin was discontinued when a total cumulative dose of 200 units/m<sup>2</sup> was reached
+
**Cycles 1 up to 10: 10 units/m<sup>2</sup> IV bolus once per day on days 1 & 8
 
*[[Methotrexate (MTX)]] 25 mg/m<sup>2</sup> IV bolus once per day on days 1 & 8
 
*[[Methotrexate (MTX)]] 25 mg/m<sup>2</sup> IV bolus once per day on days 1 & 8
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> at a concentration of 1 mg/mL normal saline IV given at a rate of 1 mg/min once on day 1
+
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, given at a rate of 1 mg/min
 
+
====Supportive therapy====
====Supportive medications====
+
*Normal saline IV at 250 mL/hour, starting 1 hour prior to cisplatin and continued for at least 6 hours after completion of cisplatin
*Normal saline IV at 250 mL/hour, starting 1 hour before [[Cisplatin (Platinol)]] and continued at least 6 hours after completion of [[Cisplatin (Platinol)]]
+
*[[Furosemide (Lasix)]] 40 mg IV once on day 1, given prior to cisplatin
*Furosemide (Lasix) 40 mg IV once prior to [[Cisplatin (Platinol)]]
+
'''21-day cycles (patients who achieved CR discontinued therapy after 6 cycles)'''
 
+
</div></div><br>
'''21-day cycles, given until disease progression; patients who achieved complete remission discontinued therapy after 6 cycles'''
+
<div class="toccolours" style="background-color:#ee6b6e">
 
+
===Regimen variant #2 {{#subobject:99e731|Variant=1}}===
===Regimen #2 {{#subobject:99e731|Variant=1}}===
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
''The NCCN, Penile Cancer version 1.2013, says that "bleomycin-containing regimens were associated with unacceptable toxicity and are no longer recommended."''
+
!style="width: 33%"|Study
{| class="wikitable" style="width: 100%; text-align:center;"  
+
!style="width: 33%"|Dates of enrollment
!Study
+
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
![[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
|[http://www.jurology.com/article/S0022-5347%2801%2962402-9/abstract Corral et al. 1998]
+
|[https://doi.org/10.1016/S0022-5347(01)62402-9 Corral et al. 1998]
|style="background-color:#91cf61"|Phase II
+
|1988-03 to 1994-01
 +
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
 
|}
 
|}
 
+
''Note: 21 of 29 evaluable patients in Corral et al. 1998 had penile cancer. Please see the paper for additional variations in the protocol, including some patients being treated with intraarterial therapy. This is likely of historic interest due to the toxicity of bleomycin-containing regimens.''  
''21 of 29 evaluable patients in Corral et al. 1998 had penile cancer. Please see the paper for additional variations in the protocol, including some patients being treated with intraarterial therapy.''  
+
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Bleomycin (Blenoxane)]] 10 mg/m<sup>2</sup> IV once per day on days 2 to 6  
 
*[[Bleomycin (Blenoxane)]] 10 mg/m<sup>2</sup> IV once per day on days 2 to 6  
Line 181: Line 173:
 
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV over 3 hours once per day on days 2 to 6
 
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV over 3 hours once per day on days 2 to 6
 
**Note: Corral et al. 1998 does not specify which days cisplatin is given on. Pagliaro et al. 2009 specifies that cisplatin is given on days 2 to 6. For Corral et al. 1998, the 5 day course is inferred based on the paper saying that the total dosage--presumably per cycle--was 100 mg/m<sup>2</sup>.
 
**Note: Corral et al. 1998 does not specify which days cisplatin is given on. Pagliaro et al. 2009 specifies that cisplatin is given on days 2 to 6. For Corral et al. 1998, the 5 day course is inferred based on the paper saying that the total dosage--presumably per cycle--was 100 mg/m<sup>2</sup>.
 
+
====Supportive therapy====
====Supportive medications====
+
*[[Leucovorin (Folinic acid)]] 25 mg PO every 6 hours on days 2 to 4, 16 to 18, 23 to 25, starting 24 hours after each dose of methotrexate
*[[Folinic acid (Leucovorin)]] 25 mg PO every 6 hours x 12 doses, starting 24 hours after each dose of [[Methotrexate (MTX)]]
 
 
 
 
'''28-day cycles'''
 
'''28-day cycles'''
 
+
</div></div>
 
===References===
 
===References===
# Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998 Nov;160(5):1770-4. [http://www.jurology.com/article/S0022-5347%2801%2962402-9/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9783949 PubMed]
+
# Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998 Nov;160(5):1770-4. [https://doi.org/10.1016/S0022-5347(01)62402-9 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/9783949/ PubMed]
# Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999 Jun;161(6):1823-5. [http://www.jurology.com/article/S0022-5347(05)68815-5/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10332445 PubMed] content property of [http://hemonc.org HemOnc.org]
+
# '''SWOG 8520:''' Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999 Jun;161(6):1823-5. [https://doi.org/10.1016/S0022-5347(05)68815-5 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/10332445/ PubMed] content property of [https://hemonc.org HemOnc.org]
# '''Review''': Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [http://link.springer.com/article/10.1007%2Fs00345-008-0310-z link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18682961 PubMed]
+
# '''Review:''' Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [https://doi.org/10.1007/s00345-008-0310-z link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18682961/ PubMed]
  
==Cisplatin & Fluorouracil {{#subobject:f70357|Regimen=1}}==
+
==Cisplatin & Fluorouracil (CF) {{#subobject:f70357|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
+
<div class="toccolours" style="background-color:#eeeeee">
|-
 
|[[#top|back to top]]
 
|}
 
 
===Regimen {{#subobject:1e2b1c|Variant=1}}===
 
===Regimen {{#subobject:1e2b1c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!Study
+
!style="width: 33%"|Study
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/1538445 Shammas et al. 1992]
+
|[https://doi.org/10.1016/s0022-5347(17)37327-5 Shammas et al. 1992]
|style="background-color:#ffffbe"|Pilot, <20 pts
+
|1985-1990
 +
|style="background-color:#ffffbe"|Pilot, fewer than 20 pts
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once once on day 1
+
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 5
+
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 5000 mg/m<sup>2</sup>)
 
+
</div></div>
 
===References===
 
===References===
# Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1538445 PubMed]
+
# Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. [https://doi.org/10.1016/s0022-5347(17)37327-5 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/1538445/ PubMed]
 
+
==Cisplatin & Irinotecan (IC) {{#subobject:606813|Regimen=1}}==
==Cisplatin & Irinotecan {{#subobject:606813|Regimen=1}}==
+
<div class="toccolours" style="background-color:#eeeeee">
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|[[#top|back to top]]
 
|}
 
 
===Regimen {{#subobject:ec3985|Variant=1}}===
 
===Regimen {{#subobject:ec3985|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!Study
+
!style="width: 33%"|Study
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[http://annonc.oxfordjournals.org/content/19/7/1304.long Theodore et al. 2008 (EORTC 30992)]
+
|[https://doi.org/10.1093/annonc/mdn149 Theodore et al. 2008 (EORTC 30992)]
|style="background-color:#91cf61"|Phase II
+
|2004-05 to 2006-01
 +
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given second'''
 
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given second'''
 
*[[Irinotecan (Camptosar)]] 60 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, '''given first'''
 
*[[Irinotecan (Camptosar)]] 60 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, '''given first'''
 
+
====Supportive therapy====
====Supportive medications====
+
*Adequate [[:Category:Hydration|hydration]] with cisplatin, per guidelines at each investigator's site
*Adequate hydration with cisplatin, per guidelines at each investigator's site
 
 
*Antiemetic medication per routine local practice.  
 
*Antiemetic medication per routine local practice.  
 
*"Systematic premedication with atropine as of the first cycle of treatment was at the investigator's discretion but was not recommended."
 
*"Systematic premedication with atropine as of the first cycle of treatment was at the investigator's discretion but was not recommended."
 
 
'''28-day cycles, with up to 4 cycles before surgery in the neoadjuvant setting for T3 or N1 to N2; up to 8 cycles for patients with T4, N3, or M+ distant metastatic disease'''
 
'''28-day cycles, with up to 4 cycles before surgery in the neoadjuvant setting for T3 or N1 to N2; up to 8 cycles for patients with T4, N3, or M+ distant metastatic disease'''
 
+
</div></div>
 
===References===
 
===References===
# Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; EORTC Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. [http://annonc.oxfordjournals.org/content/19/7/1304.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18417462 PubMed]
+
# '''EORTC 30992:''' Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; [[Study_Groups#EORTC|EORTC]] Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. Epub 2008 Apr 15. [https://doi.org/10.1093/annonc/mdn149 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/18417462/ PubMed]
  
 
==Paclitaxel monotherapy {{#subobject:3bde8f|Regimen=1}}==
 
==Paclitaxel monotherapy {{#subobject:3bde8f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
+
<div class="toccolours" style="background-color:#eeeeee">
|-
 
|[[#top|back to top]]
 
|}
 
 
===Regimen {{#subobject:2565c5|Variant=1}}===
 
===Regimen {{#subobject:2565c5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!Study
+
!style="width: 33%"|Study
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[http://www.sciencedirect.com/science/article/pii/S0302283811008967 Di Lorenzo et al. 2011]
+
|[https://doi.org/10.1016/j.eururo.2011.08.028 Di Lorenzo et al. 2011]
|style="background-color:#91cf61"|Phase II
+
|2004-04 to 2011-01
 +
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
 
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
 
+
====Supportive therapy====
====Supportive medications====
 
 
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] could be used in later cycles if the patient developed febrile neutropenia during treatment
 
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] could be used in later cycles if the patient developed febrile neutropenia during treatment
 
*[[Dexamethasone (Decadron)]] 8 mg PO given three times, at 12 hours before, immediately before, and 12 hours after paclitaxel
 
*[[Dexamethasone (Decadron)]] 8 mg PO given three times, at 12 hours before, immediately before, and 12 hours after paclitaxel
 
 
'''21-day cycles'''
 
'''21-day cycles'''
 
+
</div></div>
 
===References===
 
===References===
# Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. [http://www.sciencedirect.com/science/article/pii/S0302283811008967 link to SD article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21871710 PubMed]
+
# Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. Epub 2011 Aug 22. [https://doi.org/10.1016/j.eururo.2011.08.028 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21871710/ PubMed]
  
 
==Panitumumab monotherapy {{#subobject:92a67f|Regimen=1}}==
 
==Panitumumab monotherapy {{#subobject:92a67f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
+
<div class="toccolours" style="background-color:#eeeeee">
|-
 
|[[#top|back to top]]
 
|}
 
 
 
 
===Regimen {{#subobject:7d9cd7|Variant=1}}===
 
===Regimen {{#subobject:7d9cd7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable" style="width: 40%; text-align:center;"  
!Study
+
!style="width: 25%"|Study
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[http://jco.ascopubs.org/content/29/22/e650.long Necchi et al. 2011]
+
|[https://doi.org/10.1200/jco.2011.34.8367 Necchi et al. 2011]
 
|style="background-color:#ffffbe"|Case report
 
|style="background-color:#ffffbe"|Case report
 
|-
 
|-
 
|}
 
|}
''Note: Necchi et al. 2011 is a case report referenced by the NCCN Guidelines, Penile Cancer version 1.2013.''
+
<div class="toccolours" style="background-color:#b3e2cd">
====Chemotherapy====
+
====Targeted therapy====
 
*[[Panitumumab (Vectibix)]] 6 mg/kg IV once on day 1
 
*[[Panitumumab (Vectibix)]] 6 mg/kg IV once on day 1
 
 
'''14-day cycles'''
 
'''14-day cycles'''
 
+
</div></div>
 
===References===
 
===References===
# Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [http://jco.ascopubs.org/content/29/22/e650.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21632506 PubMed]
+
# '''Case report:''' Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [https://doi.org/10.1200/jco.2011.34.8367 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21632506/ PubMed]
 
+
==PCF {{#subobject:edc2a7|Regimen=1}}==
==TIP {{#subobject:2169d9|Regimen=1}}==
+
PCF: '''<u>P</u>'''aclitaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
{| class="wikitable" style="float:right; margin-left: 5px;"
+
<div class="toccolours" style="background-color:#eeeeee">
|-
 
|[[#top|back to top]]
 
|}
 
No primary reference available, but the NCCN, Penile Cancer version 1.2013, says that "[[#TIP|TIP]] is a reasonable first-line treatment for patients with metastatic penile cancer." (see neoadjuvant chemotherapy section)
 
 
 
==TPF (Taxol) {{#subobject:edc2a7|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|[[#top|back to top]]
 
|}
 
TPF: '''<u>T</u>'''axol (Paclitaxel), '''<u>P</u>'''latinol (Cisplatin), '''<u>F</u>'''luorouracil
 
 
 
 
===Regimen {{#subobject:5f8356|Variant=1}}===
 
===Regimen {{#subobject:5f8356|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!Study
+
!style="width: 33%"|Study
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[http://www.europeanurology.com/article/S0302-2838(08)00835-X/fulltext/taxanes-in-combination-with-cisplatin-and-fluorouracil-for-advanced-penile-cancer-preliminary-results Pizzocaro et al. 2009]
+
|[https://doi.org/10.1016/j.eururo.2008.07.014 Pizzocaro et al. 2009]
|style="background-color:#ffffbe"|Pilot, <20 pts
+
|2004-2006
 +
|style="background-color:#ffffbe"|Pilot, fewer than 20 pts
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 120 mg/m<sup>2</sup> in 500 mL 5% glucose solution IV once on day 1, '''given first'''
+
*[[Paclitaxel (Taxol)]] 120 mg/m<sup>2</sup> IV once on day 1, '''given first'''
 
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 2
 
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day in 2 liters half normal 2.5% glucose saline IV continuous infusion on days 2 to 5
+
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 2 (total dose per cycle: 4000 mg/m<sup>2</sup>)
 
+
====Supportive therapy====
====Supportive medications====
 
 
*"Corticosteroids, antihistamines, and an H2 antagonist were administered before starting paclitaxel"
 
*"Corticosteroids, antihistamines, and an H2 antagonist were administered before starting paclitaxel"
*"Antiemetic drugs and glutathione were administered before [[Cisplatin (Platinol)]]"
+
*"Antiemetic drugs and glutathione were administered prior to cisplatin"
*1 liter half normal 2.5% glucose saline with 20 mEq potassium chloride and 10 mEq magnesium sulfate (MgSO4) IV given twice, before and after [[Cisplatin (Platinol)]]
+
*1 liter half normal 2.5% glucose saline with 20 mEq potassium chloride and 10 mEq magnesium sulfate (MgSO4) IV given twice, before and after cisplatin
 
 
 
'''21-day cycles'''; "two patients received more than the standard four courses"
 
'''21-day cycles'''; "two patients received more than the standard four courses"
 
+
</div></div>
 
===References===
 
===References===
# Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009 Mar;55(3):546-51. Epub 2008 Jul 14. [http://www.europeanurology.com/article/S0302-2838(08)00835-X/fulltext/taxanes-in-combination-with-cisplatin-and-fluorouracil-for-advanced-penile-cancer-preliminary-results link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18649992 PubMed]
+
# Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009 Mar;55(3):546-51. Epub 2008 Jul 14. [https://doi.org/10.1016/j.eururo.2008.07.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18649992/ PubMed]
  
 
[[Category:Penile cancer regimens]]
 
[[Category:Penile cancer regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
[[Category:Genitourinary cancers]]
+
[[Category:Male genital cancers]]

Latest revision as of 23:34, 15 July 2024

Section editor
Alikhaki.jpg
Ali Raza Khaki, MD
Stanford University
Palo Alto, CA, USA

LinkedIn
9 regimens on this page
10 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

EAU/ASCO

ESMO

NCCN

Neoadjuvant chemotherapy

TIP

TIP: Taxol (Paclitaxel), Ifosfamide, Platinol (Cisplatin)

Regimen

Study Dates of enrollment Evidence
Pagliaro et al. 2010 (MDACC ID99-194) 2000-04 to 2008-09 Phase 2

Note: cycle was repeated on day 22 if the patient's ANC was at least 1400/μL and platelet count was at least 100 x 109/L. Some guidelines state that it is reasonable to give adjuvant TIP if it was not given preoperatively and pathology shows high-risk features, or to give first-line TIP in the metastatic setting; to our knowledge, there are no primary references to support this practice.

Chemotherapy

  • Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
  • Ifosfamide (Ifex) 1200 mg/m2 IV over 2 hours once per day on days 1 to 3
  • Cisplatin (Platinol) 25 mg/m2 IV over 2 hours once per day on days 1 to 3
    • Administered intravenously in 250 mL of normal saline containing 12.5 g of mannitol

Supportive therapy

  • Mesna (Mesnex) 400 mg/m2 IV once per day on days 1 to 3, prior to each dose of ifosfamide, then 200 mg/m2 IV twice per day on days 1 to 3, at 4 and 8 hours after each dose of ifosfamide
  • hydration with 3 liters of a solution of 5% dextrose, sodium chloride, potassium chloride, magnesium sulfate, and mannitol, given after cisplatin
  • One of the following dexamethasone doses:
  • Diphenhydramine (Benadryl) 50 mg IV once on day 1, prior to paclitaxel
  • One of the following H2 blockers:
  • "The use of prophylactic G-CSF was allowed but not required"

21- to 28-day cycle for 4 cycles

Subsequent treatment

References

  1. MDACC ID99-194: Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. Epub 2010 Jul 12. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00512096

VBM (Vincristine)

VBM: Vincristine, Bleomycin, Methotrexate

Regimen

Study Dates of enrollment Evidence
Pizzocaro et al. 1988 1979-1985 Pilot, fewer than 20 pts

Note: this is of historic interest given the toxicity of bleomycin-containing regimens.

Preceding treatment

Chemotherapy

7-day cycle for 12 cycles

Subsequent treatment

References

  1. Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4. link to original article dosing details in manuscript have been reviewed by our editors PubMed
  2. Review: Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed

Adjuvant chemotherapy

DCF

DCF: Docetaxel, Cisplatin, Fluorouracil

Regimen

Study Evidence
Necchi et al. 2011 Case report

Preceding treatment

Chemotherapy

21-day cycle for 3 cycles

References

  1. Case report: Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. link to original article dosing details in manuscript have been reviewed by our editors PubMed

Metastatic or unresectable disease

BMP

BMP: Bleomycin, Methotrexate, Platinol (Cisplatin)
MPB: Methotrexate, Platinol (Cisplatin), Bleomycin

Regimen variant #1

Study Dates of enrollment Evidence
Haas et al. 1999 (SWOG 8520) 1986-1994 Phase 2

Note: This is likely of historic interest due to the toxicity of bleomycin-containing regimens. Bleomycin was discontinued when a total cumulative dose of 200 units/m2 was reached.

Chemotherapy

Supportive therapy

  • Normal saline IV at 250 mL/hour, starting 1 hour prior to cisplatin and continued for at least 6 hours after completion of cisplatin
  • Furosemide (Lasix) 40 mg IV once on day 1, given prior to cisplatin

21-day cycles (patients who achieved CR discontinued therapy after 6 cycles)


Regimen variant #2

Study Dates of enrollment Evidence
Corral et al. 1998 1988-03 to 1994-01 Phase 2

Note: 21 of 29 evaluable patients in Corral et al. 1998 had penile cancer. Please see the paper for additional variations in the protocol, including some patients being treated with intraarterial therapy. This is likely of historic interest due to the toxicity of bleomycin-containing regimens.

Chemotherapy

  • Bleomycin (Blenoxane) 10 mg/m2 IV once per day on days 2 to 6
    • Note: Pagliaro et al. 2009 lists a "dosage of 50 mg/m2 on days 2 to 6," which could be misinterpreted as 50 mg/m2 for each dose, which is in contrast to the 50 mg/m2 for each cycle that Corral et al. 1998 describes.
  • Methotrexate (MTX) 200 mg/m2 IV once per day on days 1, 15, 22
  • Cisplatin (Platinol) 20 mg/m2 IV over 3 hours once per day on days 2 to 6
    • Note: Corral et al. 1998 does not specify which days cisplatin is given on. Pagliaro et al. 2009 specifies that cisplatin is given on days 2 to 6. For Corral et al. 1998, the 5 day course is inferred based on the paper saying that the total dosage--presumably per cycle--was 100 mg/m2.

Supportive therapy

  • Leucovorin (Folinic acid) 25 mg PO every 6 hours on days 2 to 4, 16 to 18, 23 to 25, starting 24 hours after each dose of methotrexate

28-day cycles

References

  1. Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998 Nov;160(5):1770-4. link to original article dosing details in manuscript have been reviewed by our editors PubMed
  2. SWOG 8520: Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999 Jun;161(6):1823-5. link to original article dosing details in manuscript have been reviewed by our editors PubMed content property of HemOnc.org
  3. Review: Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed

Cisplatin & Fluorouracil (CF)

Regimen

Study Dates of enrollment Evidence
Shammas et al. 1992 1985-1990 Pilot, fewer than 20 pts

Chemotherapy

References

  1. Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. link to original article dosing details in abstract have been reviewed by our editors PubMed

Cisplatin & Irinotecan (IC)

Regimen

Study Dates of enrollment Evidence
Theodore et al. 2008 (EORTC 30992) 2004-05 to 2006-01 Phase 2

Chemotherapy

Supportive therapy

  • Adequate hydration with cisplatin, per guidelines at each investigator's site
  • Antiemetic medication per routine local practice.
  • "Systematic premedication with atropine as of the first cycle of treatment was at the investigator's discretion but was not recommended."

28-day cycles, with up to 4 cycles before surgery in the neoadjuvant setting for T3 or N1 to N2; up to 8 cycles for patients with T4, N3, or M+ distant metastatic disease

References

  1. EORTC 30992: Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; EORTC Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. Epub 2008 Apr 15. link to original article dosing details in manuscript have been reviewed by our editors PubMed

Paclitaxel monotherapy

Regimen

Study Dates of enrollment Evidence
Di Lorenzo et al. 2011 2004-04 to 2011-01 Phase 2

Chemotherapy

Supportive therapy

  • G-CSF could be used in later cycles if the patient developed febrile neutropenia during treatment
  • Dexamethasone (Decadron) 8 mg PO given three times, at 12 hours before, immediately before, and 12 hours after paclitaxel

21-day cycles

References

  1. Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. Epub 2011 Aug 22. link to original article dosing details in manuscript have been reviewed by our editors PubMed

Panitumumab monotherapy

Regimen

Study Evidence
Necchi et al. 2011 Case report

Targeted therapy

14-day cycles

References

  1. Case report: Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. link to original article dosing details in manuscript have been reviewed by our editors PubMed

PCF

PCF: Paclitaxel, Cisplatin, Fluorouracil

Regimen

Study Dates of enrollment Evidence
Pizzocaro et al. 2009 2004-2006 Pilot, fewer than 20 pts

Chemotherapy

Supportive therapy

  • "Corticosteroids, antihistamines, and an H2 antagonist were administered before starting paclitaxel"
  • "Antiemetic drugs and glutathione were administered prior to cisplatin"
  • 1 liter half normal 2.5% glucose saline with 20 mEq potassium chloride and 10 mEq magnesium sulfate (MgSO4) IV given twice, before and after cisplatin

21-day cycles; "two patients received more than the standard four courses"

References

  1. Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009 Mar;55(3):546-51. Epub 2008 Jul 14. link to original article PubMed